If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Regulatory News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 155.00
Bid: 150.00
Ask: 160.00
Change: 0.00 (0.00%)
Spread: 10.00 (6.667%)
Open: 155.00
High: 155.00
Low: 155.00
Prev. Close: 155.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

7 Mar 2017 10:54

RNS Number : 7446Y
Faron Pharmaceuticals Oy
07 March 2017
 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached:

 

Faron Pharmaceuticals Oy

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.

 

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

Yes

 

Other (please specify):

 

3. Full name of person(s) subject to thenotification obligation:

 

Legal & General Group Plc (L&G)

 

Legal & General (Unit Trust Managers) Limited (UTM)

 

4. Full name of shareholder(s)  (if different from 3.):

 

N/A

 

 

5. Date of the transaction and date onwhich the threshold is crossed orreached:

 

03 March 2017

6. Date on which issuer notified:

07 March 2017

7. Threshold(s) that is/are crossed orreached:

 

UTM (Below 5%)

 

8. Notified details:

 

A: Voting rights attached to shares

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

 

Numberof shares

Number of votingrights

% of voting rights

Direct

Indirect

Direct

Indirect

ORD NPV

1,365,000.00

 Below 5%

-

 Below 5%

-

 Below 5%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

Expirationdate

 

Exercise/Conversion Period

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

 

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

 

Exercise price

 

Expiration date

 

Exercise/Conversion period

 

Number of voting rights instrument refers to

 

 

% of voting rights

 

 

 

Nominal

Delta

 

 

 

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 

 UTM

(Below 5%)

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

 

Legal & General Group Plc (Direct and Indirect) (Group) ( 1,565,000 - 5.64%= Total Position)

Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect) ( 1,565,000 - 5.64%= Total Position)

Legal & General Investment Management Limited (Indirect) (LGIM) ( 1,565,000 - 5.64%= Total Position)

Legal & General (Unit Trust Managers) Limited (Below 5% = UTM)

Legal & General Group Plc (Direct) (L&G) ( Below 3% = LGAS, & PMC)

Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD)

Legal & General Insurance Holdings Limited (Direct) (LGIH) (LGAS)

Legal & General Assurance (Pensions Management) Limited (PMC)

Legal & General Assurance Society Limited (LGAS)

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will ceaseto hold:

N/A

12. Date on which proxy holder will cease to holdvoting rights:

N/A

 

 

 

 

13. Additional information:

Notification using the total voting rights figure of  27,734,044

14. Contact name:

Victoria Davies (LGIM)

15. Contact telephone number:

029 2035 4147

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLKMGGFGNMGNZM
Date   Source Headline
17th Aug 20204:41 pmRNSSecond Price Monitoring Extn
17th Aug 20204:36 pmRNSPrice Monitoring Extension
27th Jul 20207:00 amRNSChange of Adviser
20th Jul 20204:41 pmRNSSecond Price Monitoring Extn
20th Jul 20204:35 pmRNSPrice Monitoring Extension
8th Jul 20203:00 pmRNSManagers’ transactions
16th Jun 20207:01 amRNSFaron hosts virtual R&D Day today
16th Jun 20207:00 amRNSFaron update on pipeline progress ahead of R&D Day
15th Jun 20207:00 amRNSFaron receives EUR 2.1 million funding from BF
11th Jun 20207:00 amRNSFaron selected for EUR2.5 million grant from EIC
1st Jun 20207:00 amRNSMATINS Update
28th May 20207:00 amRNSFaron announces R&D Day to be held in June
20th May 20207:00 amRNSPublication in Intensive Care Medicine
18th May 20204:00 pmRNSResults of the Annual General Meeting
13th May 20201:00 pmRNSExercise of options
12th May 20206:00 pmRNSManagers’ transactions
11th May 202010:00 amRNSFaron receives grant from Business Finland
5th May 20207:00 amRNSClevegen manufacturing agreement
29th Apr 20201:15 pmRNSHolding(s) in Company
27th Apr 20202:45 pmRNSHolding(s) in Company
27th Apr 20207:00 amRNSTraumakine to be a part of WHO’s Solidarity trial
23rd Apr 20201:00 pmRNSUpdate on results of Placing and issue of equity
22nd Apr 20207:00 amRNSResult of placing and issue price
21st Apr 20204:45 pmRNSProposed Placing
15th Apr 202011:06 amRNSSecond Price Monitoring Extn
15th Apr 202011:00 amRNSPrice Monitoring Extension
14th Apr 20207:00 amRNSNotice of Annual General Meeting
3rd Apr 20202:45 pmRNSAGM to be postponed
1st Apr 20207:00 amRNSREMAP-CAP to study IFN beta-1a effect in COVID-19
30th Mar 20207:00 amRNSPart 1 of the MATINS Phase I/II Study Completed
26th Mar 202010:00 amRNSCorrection to Faron´s Annual Report 2019
25th Mar 20207:28 amRNSFaron´s Annual Report 2019 published
20th Mar 202011:30 amRNSNotice of Annual General Meeting
20th Mar 20207:00 amRNSFinal Results for the year ended December 31, 2019
19th Mar 20204:41 pmRNSSecond Price Monitoring Extn
19th Mar 20204:36 pmRNSPrice Monitoring Extension
12th Mar 20204:44 pmRNSSecond Price Monitoring Extn
12th Mar 20204:38 pmRNSPrice Monitoring Extension
9th Mar 20207:00 amRNSFDA accepts protocol for new Traumakine trial
5th Mar 20207:00 amRNSMATINS update
2nd Mar 20207:00 amRNSFaron to acquire AOC3 antagonist platform
26th Feb 20207:05 amRNSPrice Monitoring Extension
26th Feb 20207:01 amRNSSecond Price Monitoring Extn
26th Feb 20207:00 amRNSPrice Monitoring Extension
25th Feb 20202:05 pmRNSSecond Price Monitoring Extn
25th Feb 20202:00 pmRNSPrice Monitoring Extension
25th Feb 202011:00 amRNSPrice Monitoring Extension
24th Feb 20204:41 pmRNSSecond Price Monitoring Extn
24th Feb 20204:35 pmRNSPrice Monitoring Extension
18th Feb 202011:06 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.